바로가기
메인메뉴로 바로가기
콘텐츠 바로가기
하단메뉴로 바로가기
패밀리사이트 바로가기


진료과

  • 연세암병원-종양내과, 위암센터

전문진료분야

  • <종양내과> 위암, 흑색종, 항암약물치료, 신약치료

진료시간표

인터넷진료예약
의사시간표
진료시간
오전 암병원 암병원
오후 암병원 암병원

교육 및 임상 경력

  • 세브란스  병원,  인턴
  • 세브란스  병원,  내과  전공의
  • 연세의료원  암센터,  종양내과  강사
  • 연세의료원  암센터,  종양내과  임상  연구  조교수
  • 가천의대  길병원  혈액종양내과  임상  조교수
  • 현)  연세의대  내과학교실  종양내과  조교수

학술관련경력

  • 대한내과학회 정회원
  • 대한암학회 정회원
  • 대한항암요법연구회(KCSG) 정회원
  • 대한종양내과학회(KACO) 정회원
  • 미국임상암학회(ASCO) 정회원
  • 미국암연구학회(AACR) 정회원
  •  
  • [수상경력]
  • 2008년 한국암학술재단 암전문가 교육사업
  • 2009년 한국암학술재단 장학생
  • 2009년 보건산업 진흥원 임상 의과학자 양성과정
  • 2010년 RKOF Best abstract
  • 2010년 보건산업 진흥원 임상 의과학자 양성과정
  • 2010년 임상시험 전문 인력 양성 특성화 교육지원사업-국내연수
  • 2010년 가천의대길병원 중점과제 연구비 수혜
  • 2010년 제 3회 한국임상암학회 한미 우수 Presentation상
  • 2011년 제 4회 한국임상암학회 한미 우수 Presentation상
  • 2012년 연세대학교 내과학교실 학술연구비 수혜
  • 2013년 한국임상암학회-머크세르노 대장암 학술상 수상
  • 2013년 제 6회 한국임상암학회 우수 Presentation상
  • 2014년 연세대학교 의과대학 내과학교실 학술연구비 수혜
  • 2014년 한국연구재단 신진연구지원사업 연구비 수혜
  • 2014년 연세대학교 미래선도지원 사업 연구비 수혜
  • 2017년 보령-KCSG 젊은 연구자상

주요 관심분야

  • 위암, 흑색종의 신약 항암치료
  • 유전자 맞춤 임상시험
  • 약물 반응 예측 및 저항 기전 연구

학력사항

  • 1999 연세대학교 생물학과 졸업
  • 2003 연세대학교 의과대학 졸업
  • 2008 연세대학교 의과대학 대학원 석사
  • 2017 연세대학교 의과대학 대학원 박사

논문

  • Jung M, Ryu MH, Oh DY, Kang M, Zang DY, Hwang IG, Lee KW, Kim KH, Shim BY, Song EK, Sym SJ, Han HS, Park YL, Kim JS, Lee HW, Lee MH, Koo DH, Song HS, Lee N, Yang SH, Choi DR, Hong YS, Lee KE, Maeng CH, Baek JH, Kim S, Kim YH, Rha SY, Cho JY, Kang YK. Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). Gastric Cancer. 2018 Feb 9. doi: 10.1007/s10120-018-0806-1. [Epub ahead of print] - Co-1st author
  • Lee CK, Jung M, Kim HS, Jung I, Shin DB, Kang SY, Zang DY, Kim KH, Lee MH, Kim BS, Lee KH, Cheong JH, Hyung WJ, Noh SH, Chung HC, Rha SY. S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. Cancer Res Treat. 2018 Feb 5. doi: 10.4143/crt.2018.028. [Epub ahead of print]-Co-1st author
  • Kim HS, Ryu MH, Zang DY, Park SR, Han B, Kang WK, Rha SY, Jung M, Kim JS, Kang BW, Lee KH, Rho SY, Kim JH, Kim KC, Cho JW, Choi DR, Lim H, Kang HS, Soh JS, Kim MJ, Seo J, Kang YK. Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11. Gastric Cancer. 2018 Jan 25. doi: 10.1007/s10120-018-0794-1. [Epub ahead of print]
  • Kim JH, Shin SJ, Heo SJ, Choe EA, Kim CG, Jung M, Keum KC, Yoon JS, Lee SC, Shin SJ. Prognoses and Clinical Outcomes of Primary and Recurrent Uveal Melanoma. Cancer Res Treat. 2017 Dec 28. doi: 10.4143/crt.2017.534. [Epub ahead of print]
  • Ji Soo Park, Jong-Chan Youn, Chi Young Shim, Geu-Ru Hong, Choong-Kun Lee, Jee Hyung Kim, Hyung Soon Park, Su Jin Heo, Seung Hoon Beom, Hyo Song Kim, Sun Young Rha, Hyun Cheol Chung, Seok-Min Kang, and Minkyu Jung. Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. Oncotarget. 2017; 8:61837-61845-Corresponding author
  • Kim CG, Ahn JB, Shin SJ, Beom SH, Heo SJ, Park HS, Kim JH, Choe EA, Koom WS, Hur H, Min BS, Kim NK, Kim H, Kim C, Jung I, Jung M. Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery. BMC Cancer. 2017 Sep 2;17(1):615-Corresponding author
  • Park JS, Lee N, Beom SH, Kim HS, Lee CK, Rha SY, Chung HC, Yun M, Cho A, Jung M. The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status. Gastric Cancer. 2017 Jun 22. doi: 10.1007/s10120-017-0739-0. [Epub ahead of print] -Corresponding author
  • Kim HS, Lee H, Shin SJ, Beom SH, Jung M, Bae S, Lee EY, Park KH, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Park JC, Shin SK, Lee SK, Lee YC, Koom WS7, Lim JS, Chung HC, Noh SH, Rha SY, Kim H, Paik S. Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer. Oncotarget. 2017 Jun 13;8(24):38389-38398.
  • Lee CK, Kim SS, Park S, Kim C, Heo SJ, Lim JS, Kim H, Kim HS, Rha SY, Chung HC, Park S, Jung M. Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. Oncotarget. 2017 May 9;8(19):31169-31179-Corresponding author
  • HS Kim, M Jung, HN Kang, H Kim, C-W Park, S-M Kim, SJ Shin, SH Kim, SG Kim, EK Kim, MR Yun, Z Zheng, KY Chung, J Greenbowe, SM Ali, T-M Kim and BC Cho. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. Oncogene. 2017 Jan 16. Epub. ?Co-1st author
  • Kim CG, Ahn JB, Jung M, Beom SH, Heo SJ, Kim JH, Kim YJ, Kim NK, Min BS, Koom WS, Kim H, Roh YH, Ma BG, Shin SJ. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer. Ann Surg Oncol. 2017 Jan;24(1):227-235.
  • Yoon HI, Koom WS, Kim TH, Ahn JB, Jung M, Kim TI, Kim H, Shin SJ, Kim NK. Upfront Systemic Chemotherapy and Short-Course Radiotherapy with Delayed Surgery for Locally Advanced Rectal Cancer with Distant Metastases: Outcomes, Compliance, and Favorable Prognostic Factors. PLoS One. 2016 Aug 18;11(8):e0161475.
  • Kim HS, Shin SJ, Beom SH, Jung M, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Noh SH, Chung H, Park JC, Shin SK, Lee SK, Lee YC, Koom WS, Lim JS, Chung HC, Rha SY, Kim H. Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. Oncotarget. 2016 Jul 12;7(28):44608-44620.
  • Kim CG, Ahn JB, Jung M, Beom SH, Kim C, Kim JH, Heo SJ, Park HS, Kim JH, Kim NK, Min BS, Kim H, Koom WS, Shin SJ. Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. Br J Cancer. 2016 Jun 28;115(1):25-33
  • Jung M, Lee J, Kim TM, Lee DH, Kang JH, Oh SY, Lee SJ, Shin SJ. Ipilimumab Real-world Efficacy and Safety in Korean melanoma Patients from the Korean Named-Patient Program Cohort. Cancer Res Treat. 2017 Jan;49(1):44-53. - Co-1st author
  • Lim SM, Cho BC, Kim SW, Kang SY, Heo DS, Kim HT, Lee DH, Kim DW, Jung M, Choi JH, Shim HS, Choi JR, Kim JH. A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). Lung Cancer. 2016 Mar;93:1-8.
  • Lim SM, Kim H, Kang B, Kim HS, Rha SY, Noh SH, Hyung WJ, Cheong JH, Kim HI, Chung HC, Yun M, Cho A, Jung M. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. Ann Nucl Med. 2016 May;30(4):279-86. -Corresponding author
  • Kim KH, Shin SJ, Cho MS, Ahn JB, Jung M, Kim TI, Park YS, Kim H, Kim NK, Koom WS. A phase II study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis. Radiother Oncol. 2015 Dec 16. pii: S0167-8140(15)00649-0. doi: 10.1016/j.radonc.2015.11.029. [Epub ahead of print]
  • Jung M, Shin SJ, Koom WS, Jung I, Keum KC, Hur H, Min BS, Baik SH, Kim NK, Kim H, Lim JS, Hong SP, Kim TI, Roh JK, Park YS, Ahn JB. A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):1015-22.
  • Park HS, Jung M, Shin SJ, Heo SJ, Kim CG, Lee MG, Beom SH, Lee CY, Lee JG, Kim DJ, Ahn JB. Benefit of Adjuvant Chemotherapy After Curative Resection of Lung Metastasis in Colorectal Cancer. Ann Surg Oncol. 2015 Oct 29. [Epub ahead of print] -Corresponding author
  • Lee CK, Jung M, Choi HJ, Kim HR, Kim HS, Roh MR, Ahn JB, Chung HC, Heo SJ, Rha SY, Shin SJ. Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients who Failed First-line Therapy Containing Darcabazine. Cancer Res Treat. 2015 Feb 16. doi: 10.4143/crt.2014.261. [Epub ahead of print]
  • Heo SJ, Lee CK, Hahn KY, Kim G, Hur H, Choi SH, Han KS, Cho A, Jung M. A Case of von Hippel-Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas. Cancer Res Treat. 2015 Feb 17. doi: 10.4143/crt.2014.299. [Epub ahead of print] -Corresponding author
  • Lee CK, Jung M, Jung I, Heo SJ, Jeong YH, An JY, Kim HI, Cheong JH, Hyung WJ, Noh SH, Kim HS, Rha SY, Chung HC. Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy. Ann Surg. 2015 Jan 8. [Epub ahead of print]-Corresponding author
  • Lim SM, Jung M, Shin SJ, Baek SJ, Hur H, Min BS, Baik SH, Kim NK, Ahn JB. Clinical Implications from a Single-Center Study of Colorectal Adenocarcinoma in Transplant Recipients. Oncology. 2014 Dec 5;88(4):195-200. [Epub ahead of print]
  • Park JS, Rha SY, Chung HC, Jung M, Kim KH, Jun HJ, Kim H, An JY, Kim HI, Cheong JH, Hyung WJ, Noh SH, Kim HS. Clinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer. Oncology. 2014 Nov 13;88(3):147-156. [Epub ahead of print]
  • Zhang X, Park JS, Park KH, Kim KH, Jung M, Chung HC, Rha SY, Kim HS.PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer. Oncology. 2015;88(2):76-85
  • Park HS, Jung M, Kim HS, Kim HI, An JY, Cheong JH, Hyung WJ, Noh SH, Kim YI, Chung HC, Rha SY. Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer. Ann Surg Oncol. 2015 Jan;22(1):224-31- Co-1st author
  • Ahn HK, Jung M, Sym SJ, Shin DB, Kang SM, Kyung SY, Park JW, Jeong SH, Cho EK. A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2014 Jun 7.
  • Ahn HK, Jung M, Ha SY, Lee JI, Park I, Kim YS, Hong J, Sym SJ, Park J, Shin DB, Lee JH, Cho EK. Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer. Tumour Biol. 2014 Jun;35(6):5735-40- Co-1st author
  • Yi JH, Kim H, Jung M, Shin SJ, Choi JS, Choi GH, Baik SH, Min BS, Kim NK, Ahn JB. Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia. Oncology. 2013;85(5):283-9
  • Jung M, Lee CH, Park HS, Lee JH, Kang YA, Kim SK, Chang J, Kim DJ, Rha SY, Kim JH, Cho BC. Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung. Yonsei Med J. 2013 Jul;54(4):854-64
  • Jung M, Choi EH, Nam CM, Rha SY, Jeung HC, Lee SH, Yang WI, Roh JK, Chung HC. Application of the adjuvant! Online model to korean breast cancer patients: an assessment of prognostic accuracy and development of an alternative prognostic tool. Ann Surg Oncol. 2013 Aug;20(8):2615-24.
  • Jung M, Cho BC, Lee CH, Park HS, Kang YA, Kim SK, Chang J, Kim DJ, Rha SY, Kim JH, Lee JH. EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI. Yonsei Med J. 2012 Nov 1;53(6):1128-35
  • Jung M, Kim GW, Jung I, Ahn JB, Roh JK, Rha SY, Chung HC, Kim NK, Kim TI, Shin SJ. Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience. BMC Cancer. 2012 Oct 12;12:471
  • Jung M, Koo JS, Moon YW, Park BW, Kim SI, Park S, Lee SH, Hong S, Rha SY, Chung HC, Kim JH, Sohn J. Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy. PLoS One. 2012;7(9):e45127. doi: 10.1371/journal.pone.0045127. Epub 2012 Sep 20
  • Sym SJ, Hong J, Jung M, Park J, Cho EK, Lee WK, Chung M, Kim HS, Lee JH, Shin DB. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer. Cancer Chemother Pharmacol. 2012 Aug;70(2):277-84. Epub 2012 Jun 30.
  • Noh S, Jung JJ, Jung M, Kim KH, Lee HY, Wang B, Cho J, Kim TS, Jeung HC, Rha SY. Body fluid MMP-2 as a putative biomarker in metastatic breast cancer. Oncol Lett. 2012 Mar;3(3):699-703. Epub 2012 Jan 3.
  • Noh S, Jung JJ, Jung M, Kim TS, Park CH, Lim SJ, Jeung HC, Cheol H, Chung HC, Rha SY. MMP-2 as a Putative Biomarker for Carcinomatosis in Gastric Cancer. Hepatogastroenterology. 2011 Oct 12;58(112). doi: 10.5754/hge11209. [Epub ahead of print]
  • Hong J, Park S, Park J, Kim HS, Kim KH, Ahn JY, Rim MY, Jung M, Sym SJ, Cho EK, Shin DB, Lee JH. Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy. Leuk Lymphoma. 2011 Oct;52(10):1904-12. Epub 2011 Jun 30.
  • Jung M, Kim SH, Lee YJ, Hong S, Kang YA, Kim SK, Chang J, Rha SY, Kim JH, Kim DJ, Cho BC. Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Exp Ther Med. 2011 Jul;2(4):685-693
  • Hong J, Jung M, Kim YJ, Sym SJ, Kyung SY, Park J, Lee SP, Park JW, Cho EK, Jeong SH, Shin DB, Lee JH. Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer. Cancer Chemother Pharmacol. 2011 Jun 21. [Epub ahead of print]
  • Hong S, Shin SJ, Jung M, Jeong J, Lee YJ, Shin KH, Roh JK, Rha SY. Comparison of Long-Term Outcome between Doublet and Triplet Neoadjuvant Chemotherapy in Non-Metastatic Osteosarcoma of the Extremity. Oncology. 2011 Jun 14;80(1-2):107-117. [Epub ahead of print]
  • Shin SJ, Jung M, Jeung HC, Kim HR, Rha SY, Roh JK, Chung HC, Ahn JB. A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. Invest New Drugs. 2011 May 13. [Epub ahead of print]
  • Hong S, Cho BC, Choi HJ, Jung M, Lee SH, Park KS, Kim SK, Kim JH. Prognostic Factors in Small Cell Lung Cancer: A New Prognostic Index in Korean Patients.Oncology. 2011 Mar 16;79(3-4):293-300. [Epub ahead of print]
  • Jung M, Ahn JB, Chang JH, Suh CO, Hong S, Roh JK, Shin SJ, Rha SY. Brain metastases from colorectal carcinoma: prognostic factors and outcome. J Neurooncol. 2011 Jan;101(1):49-55. Epub 2010 May 14. J Neurooncol. 2010 May 14.
  • Jung M, Shin HJ, Rha SY, Jeung HC, Hong S, Moon YW, Kim HS, Oh KJ, Yang WI, Roh JK, Chung HC. The clinical outcome of chemotherapy induced amenorrhea in premenopausal young breast cancer patients with long term follow up. Ann Surg Oncol. 2010 Dec;17(12):3259-3268. Epub 2010 Jun 19.
  • Jung M, Jeung HC, Lee SS, Park JY, Hong S, Lee SH, Noh SH, Chung HC, Rha SY. The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites. J Cancer Res Clin Oncol. 2010 Apr;136(4):517-26. Epub 2009 Sep 23.
  • Jung JJ, Noh S, Jeung HC, Jung M, Kim TS, Noh SH, Roh JK, Chung HC, Rha SY. Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression. Cancer Sci. 2010 Oct;101(10):2200-6. doi: 10.1111/j.1349-7006.2010.01666.x. Epub 2010 Aug 22
  • Jeong J, Cho BC, Sohn JH, Choi HJ, Kim SH, Lee YJ, Jung MK, Shin SJ, Park MS, Kim SK, Chang J, Kim JH. Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: A phase II trial. Lung Cancer. 2010 Oct;70(1):77-81. Epub 2010 Mar 16.
  • Son JW, Kim JS, Lee JM, Hong SJ, Jung MK, Kim DH, Kim JS, Choi D, Jang Y. Percutaneous cardiopulmonary support in refractory no-reflow with cardiogenic shock after coronary stenting in acute myocardial infarction. Yonsei Med J. 2010 Jul;51(4):599-601.
  • Moon YW, Sohn JH, Kim YT, Chang H, Jeong JH, Lee YJ, Chang J, Kim SK, Jung M, Hong S, Choi SH, Kim JH. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided versus empirical chemotherapy in unresectable non-small cell lung cancer. Anticancer Res. 2009 Oct;29(10):4243-9.
  • Ahn JR, Jung M, Kim C, Hong MH, Chon HJ, Kim HR, Jeung HC, Hyung WJ, Lee SS, Chung HC, Noh SH, Rha SY. Prognosis of pN3 Stage Gastric Cancer. Cancer Res Treat. 2009 Jun;41(2):73-9. Epub 2009 Jun 30
  • Kim DH, Cheon JH, Moon CM, Park JJ, Han SY, Kim ES, Chung MJ, Lee JH, Jung MK, Lee SH, Son JW, Kim TI, Kim WH. Clinical efficacy of nonsurgical treatment of Crohn's disease-related intraabdominal abscess. Korean J Gastroenterol. 2009 Jan;53(1):29-35.
  • Jung MK, Hong SJ, Lee SH, Hong SJ, Son JW, Kang W, Lee YW, Hong CS, Lee JK, Park JW. Development and Validation of a Korean Allergic Rhinitis-specific Quality of Life Questionnaire (KARQLQ). Korean J Asthma Allergy Clin Immunol 2008;28:113-120
  • S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial
    CANCER RESEARCH AND TREATMENT 51/1 :1-11,2019
  • Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy
    BMC CANCER 18/1 :1116-1127,2018
  • Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer.
    ANTICANCER RESEARCH 38/11 :6,171-6,180,2018
  • Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial.
    CLINICAL CANCER RESEARCH 24/21 :5,272-5,281,2018
  • Prognoses and Clinical Outcomes of Primary and Recurrent Uveal Melanoma
    CANCER RESEARCH AND TREATMENT 50/4 :1238-1251,2018
  • Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG).
    GASTRIC CANCER 21/5 :819-830,2018
  • Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial.
    ANNALS OF SURGICAL ONCOLOGY 25/11 :3,222-3,230,2018
  • A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy
    AAPS JOURNAL 20/4 :72-87,2018
  • Predictive Nomogram for Recurrence of Stage I Colorectal Cancer After Curative Resection
    CLINICAL COLORECTAL CANCER 17/3 :513-518,2018
  • The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status
    GASTRIC CANCER 21/2 :213-224,2018
  • Correlation between KRAS mutation and 18F-FDG uptake in stage IV colorectal cancer
    ABDOMINAL RADIOLOGY 42/6 :1,621-1,626,2017
  • Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
    ONCOGENE 36/23 :3,334-3,345,2017
  • Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
    ONCOTARGET 8/37 :61,837-61,845,2017
  • Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery
    BMC CANCER 17/615 :615-625,2017
  • Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer
    ONCOTARGET 8/24 :38,389-38,398,2017
  • Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer
    ANNALS OF SURGICAL ONCOLOGY 24/1 :227-235,2017
  • Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab.
    ONCOTARGET 8/19 :31,169-31,179,2017
  • Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort
    CANCER RESEARCH AND TREATMENT 49/1 :44-53,2017
  • Benefit of Adjuvant Chemotherapy After Curative Resection of Lung Metastasis in Colorectal Cancer
    ANNALS OF SURGICAL ONCOLOGY 23/ :928-935,2016
  • Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers
    BRITISH JOURNAL OF CANCER 115/1 :25-33,2016
  • A New Practical Desensitization Protocol for Oxaliplatin-Induced Immediate Hypersensitivity Reactions: A Necessary and Useful Approach
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY 26/3 :168-176,2016
  • Upfront Systemic Chemotherapy and Short-Course Radiotherapy with Delayed Surgery for Locally Advanced Rectal Cancer with Distant Metastases: Outcomes, Compliance, and Favorable Prognostic Factors
    PLOS ONE 11/8 :e0161475-,2016
  • Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: Implications for individualized therapy
    ONCOTARGET 7/28 :44608-44620,2016
  • Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma
    ANNALS OF NUCLEAR MEDICINE 30/4 :279-286,2016
  • 수술 후 항암화학요법을 받는 대장암 환자들의 운동 인식에 대한 현상학적 연구
    한국체육학회지 55/1 :687-700,2016
  • A phase II study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis
    RADIOTHERAPY AND ONCOLOGY 118/2 :369-374,2016
  • A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806)
    LUNG CANCER 93/0 :1-8,2016
  • Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy
    ANNALS OF SURGERY 263/1 :96-102,2016
  • A Case of von Hippel?Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas
    CANCER RESEARCH AND TREATMENT 48/1 :409-414,2016
  • A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 93/5 :1015-1022,2015
  • Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine
    CANCER RESEARCH AND TREATMENT 74/4 :781-789,2015
  • Clinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer
    ONCOLOGY 88/3 :147-156,2015
  • Clinical Implications from a Single-Center Study of Colorectal Adenocarcinoma in Transplant Recipients
    ONCOLOGY 88/4 :195-200,2015
  • Proper Timing of Adjuvant Chemotherapy Affects Survival in Patients with Stage 2 and 3 Gastric Cancer
    ANNALS OF SURGICAL ONCOLOGY 22/1 :224-231,2015
  • PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer
    ONCOLOGY 88/2 :76-85,2015
  • Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer
    TUMOR BIOLOGY 35/6 :5735-5740,2014
  • A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 74/2 :277-282,2014
  • Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis.
    JOURNAL OF SURGICAL ONCOLOGY 110/2 :214-221,2014
  • Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung
    YONSEI MEDICAL JOURNAL 54/4 :854-864,2013
  • Application of the adjuvant! Online model to korean breast cancer patients: an assessment of prognostic accuracy and development of an alternative prognostic tool.
    ANNALS OF SURGICAL ONCOLOGY 20/8 :2615-2624,2013
  • EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI
    YONSEI MEDICAL JOURNAL 53/6 :1128-1135,2012
  • Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience
    BMC CANCER 12/1 :471-471,2012
  • A phase i pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy
    INVESTIGATIONAL NEW DRUGS 30/4 :1501-1510,2012
  • Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy.
    PLOS ONE 7/9 :e45127-e45127,2012
  • Body fluid MMP-2 as a putative biomarker in metastatic breast cancer
    ONCOLOGY LETTERS 3/3 :699-703,2012
  • MMP-2 as a Putative Biomarker for Carcinomatosis in Gastric Cancer
    HEPATO-GASTROENTEROLOGY 58/112 :2015-2019,2011
  • Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 2/ :685-693,2011
  • Comparison of Long-Term Outcome between Doublet and Triplet Neoadjuvant Chemotherapy in Non-Metastatic Osteosarcoma of the Extremity
    ONCOLOGY 80/1-2 :107-117,2011
  • Brain metastases from colorectal carcinoma: prognostic factors and outcome
    JOURNAL OF NEURO-ONCOLOGY 101/ :49-55,2011
  • Prognostic Factors in Small Cell Lung Cancer: A New Prognostic Index in Korean Patients
    Oncology 79/3-4 :293-300,2010
  • Percutaneous Cardiopulmonary Support in Refractory No-Reflow with Cardiogenic Shock after Coronary Stenting in Acute Myocardial Infarction
    YONSEI MEDICAL JOURNAL 51/4 :599-601,2010
  • The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up
    Annals of Surgical Oncology 17/12 :3259-3268,2010
  • Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: A phase II trial
    Lung Cancer 70/1 :77-81,2010
  • Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression
    CANCER SCIENCE 101/10 :2200-2206,2010
  • The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 136/ :517-526,2010
  • Adenosine Triphosphate-based Chemotherapy Response Assay (ATP-CRA)-guided versus Empirical Chemotherapy in Unresectable Non-small Cell Lung Cancer
    Anticancer Research 29/10 :4243-4249,2009
  • Prognosis of pN3 stage gastric cancer
    Cancer Research And Treatment 41/2 :73-79,2009
  • 크론병과 연관된 복강 내 농양에서 비수술 치료의 효용성
    Korean Journal Of Gastroenterology 53/1 :29-35,2009
  • 한국 성인 알레르기 비염 환자의 삶의 질 평가를 위한 설문지 개발 및 유용성 평가를 위한 연구
    천식 및 알레르기 28/2 :113-120,2008

정민규

진료철학
암이란 생각만으로도 무섭고, 자신과 가족에게는 생기지 않기만을 바라는 두려움의 병일 것입니다.
암환자들을 대하는 종양내과 의사로서, 이런 암과 싸우는 환자 및 가족들이 누구보다 힘드시다는 것을 잘 알고 있습니다. 힘들어 하시는 암 환자와 가족들을 위해 종양내과 의사로서 세가지 약속을 통해 도움을 드리고 싶습니다.
첫째, 환자 한 분 한 분을 치료할 때 마다, 이 환자가 바로 내 가족이라는 생각으로, 가족으로서 어떻게 치료할 것인가 하는 맘으로 고민할 것 입니다.
둘째, 지속적이고 끈임 없는 연구를 통해 환자분들께 최신의 표준화된 치료를 시행할 것입니다. 또한, 최고의 효과를 드리기 위해 새롭게 개발된 신약을 통한 다양한 임상 연구 및 새로운 치료법을 적용해 드리도록 노력 하겠습니다.
셋째, 환자와 보호자 및 다방면의 암 전문가들과 소통하는 의사가 되어, 여러분의 고민을 가능한 성심성의 것 속 시원히 대답해 드리는 의사가 되도록 노력하겠습니다.

저를 믿고 따라와주시는 환자 및 보호자들에게 예수님의 마음으로 항상 최선을 다하며, 아쉬움을 남기지 않는 따뜻한 의사가 되도록 노력하겠습니다.

콘텐츠 처음으로 이동

네크워크 링크안내/사이트 정보